5 July 2018 - Apalutamide (Erlyand) is the first medicine to be registered on the Australian Register of Therapeutic Goods that has been evaluated under the Australia-Canada-Singapore-Switzerland Consortium's New Chemical Entities Work Sharing Pilot. 

The review also utilised TGA's new priority review pathway.

Efficiencies were achieved through the work-sharing of the evaluation between Health Canada and the Therapeutic Goods Administration, with each regulator taking a lead in the evaluation of different parts of the regulatory submission dossier. However, each regulator made independent decisions regarding approval (market authorisation) of the new medicine.

Apalutamide will be sold under the name Erlyand in Australia and Erleada in Canada, and is indicated for the treatment of prostate cancer, thus expanding treatment options for patients in both countries.

Read TGA press release